Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06167486
Other study ID # CSG-2918-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 26, 2023
Est. completion date December 28, 2026

Study information

Verified date November 2023
Source Hangzhou Sumgen Biotech Co., Ltd.
Contact Zhengbo Song, Docter
Phone 86-13857153345
Email songzb@zjcc.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant Tumors who are refractory or resistant to standard therapy, or without available standard or curative therapy.


Description:

The study consists of dose escalation and dose expansion, the dose escalation will be performed in a standard 3+3 manner at the dose of 0.1mg/kg、0.5mg/kg、1 mg/kg、1.5mg/kg、2 mg/kg、2.5mg/kg and 3 mg/kg, and the dose expansion will be done in specific tumor types. Patients enrolled in the study will receive SG2918 treatment every three weeks (Q3W), until disease progression, intolerable toxicity or others, whichever occurs first.


Recruitment information / eligibility

Status Recruiting
Enrollment 117
Est. completion date December 28, 2026
Est. primary completion date December 28, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Histologically or cytologically documented advanced malignant tumors that is refractory/relapsed to standard therapies; 2. Adequate organ function; 3. ECOG Performance Status score of 0 or 1; 4. Must have at least one measurable lesion according to RECIST Version1.1; 5. Toxicity caused by prior anti-tumor therapy recovered to Grade 0 to 1 (CTCAE 5.0); 6. Must have an effective contraception during the study, starting with the Screening Visit through 7 months after the last dose of study intervention. Exclusion Criteria: 1. Has active central nervous system metastatic lesions; 2. Has Active autoimmune disease requiring systemic therapy within the past 2 years; 3. Has Grade 2 and above peripheral neuropathy; 4. Has an active infection requiring systemic therapy; 5. Has a history of any of the following cardiovascular conditions within 6 months of dosing: myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, coronary artery bypass graft, pulmonary embolism, etc; has New York Heart Association (NYHA) Class II and above congestive heart failure; LVEF<50%; 6. Has a history of hypertensive crisis or hypertensive encephalopathy; Uncontrolled hypertension though standard treatment within 14 days before the first dose (systolic blood pressure=160 mmHg and/or diastolic blood pressure=100mmHg); 7. Has known human immunodeficiency virus (HIV) and/or hepatitis B or C infections; 8. Has a history of potent CYP3A4 inhibitor with 2 weeks; 9. Has received systemic anticancer therapy, radiotherapy, or surgery within 4 weeks before the start of study treatment; 10. Have received previous treatment targeted LILRB4 or MMAE experiencing serious adverse events; 11. Have received previous immunotherapy experiencing serious adverse events that leading to permanent discontinuation; 12. Have received systemic corticosteroids (equivalent dose > 10 mg/day of prednisone) or other immunosuppressive drugs within 14 days prior to the first dose; 13. Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody (mAB) and or any components of the study intervention; 14. Any live vaccine within 28 days prior to the first dose; 15. Has a history of interstitial lung disease or active pneumonia or tracheal fistula; uncontrolled pleural, abdominal and pericardial effusion; 16. Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 year.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SG2918
The SG2918 will be administrated by intravenous infusion every 3 weeks

Locations

Country Name City State
China Hunan Cancer Hospital Changsha Hunan
China Chongqing University Cancer Hospital Chongqing Chongqing
China Zhejiang Cancer Hospital Hangzhou Zhejiang
China Shanghai first maternity and infant hospital Shanghai Shanghai
China Shanxi Provincial Cancer Hospital Taiyuan Shanxi
China Henan Cancer Hospital Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Hangzhou Sumgen Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events Number and percentage of AEs which is calculated by worst CTCAE grade by CTCAE 5.0 From the time of first dose until 30 days after last dose of SG2918
Primary Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as related to study drug, and unrelated to disease, disease progression, intercurrent illness or concomitant medications that occurs within the first cycle (three weeks) of treatment. Cycle 1 (up to 21 days)
Secondary Pharmacokinetics(PK): Cmax Maximum drug concentration after administration From the time of first dose until 30 days after last dose of SG2918
Secondary Pharmacokinetics (PK): AUC Area Under the Curve of the drug after administration From the time of first dose until 30 days after last dose of SG2918
Secondary Pharmacokinetics (PK): T1/2 Elimination half-life of the drug after administration From the time of first dose until 30 days after last dose of SG2918
Secondary Pharmacokinetics (PK): CL Clearance of the drug after administration From the time of first dose until 30 days after last dose of SG2918
Secondary Pharmacodynamic(PD): cellular biomarkers cellular biomarkers including CD4+ T cells, CD8+ T cells, Myeloid-derived suppressor cells (MDSCs) and Regulatory T cells (Tregs) From the time of first dose until 30 days after last dose of SG2918
Secondary Pharmacodynamic(PD): cytokine levels Peripheral blood cytokine levels including measurements for TNF-a,IFN-?,IL-2,IL-4?IL-6,IL-8,IL-10,IL-1ß From the time of first dose until 30 days after last dose of SG2918
Secondary Immunogenicity endpoints Levels of anti-drug antibodies(ADAs) and neutralizing antibodies (tested in ADA-positive samples) Through study completion, an average of one year,assessed up to approximately 12 months
Secondary Efficacy endpoints objective response rate (ORR) Through study completion, an average of one year,assessed up to approximately 12 months
See also
  Status Clinical Trial Phase
Completed NCT05082545 - Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT04128085 - A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors Phase 1
Recruiting NCT05229497 - A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT06223841 - A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Not yet recruiting NCT05728541 - Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05354076 - Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo Phase 2
Recruiting NCT05868876 - A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05991583 - A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05396391 - A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05235542 - A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05110807 - A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05214482 - A Study of AK112 in Advanced Malignant Tumors Phase 1/Phase 2
Not yet recruiting NCT05653284 - A Study of AK130 in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05223231 - Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors Phase 1/Phase 2
Enrolling by invitation NCT05198817 - A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients Phase 1
Active, not recruiting NCT05193721 - A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors Phase 1
Not yet recruiting NCT06226363 - Phase I Study of LNF1901 in Advanced Malignant Tumors Phase 1
Recruiting NCT04980690 - Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05877924 - A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. Phase 1
Active, not recruiting NCT04708210 - Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors Phase 1